Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Profile Name||KMT2A - AFDN|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KMT2A - AFDN||acute myeloid leukemia||predicted - sensitive||CYC065||Preclinical - Cell culture||Actionable||In a preclinical study, an acute myeloid leukemia cell line harboring KMT2A-AFDN was sensitive to treatment with CYC065 (Fadraciclib) in culture, demonstrating decreased cell viability (PMID: 32645016).||32645016|
|KMT2A - AFDN||acute myeloid leukemia||predicted - sensitive||DSP-5336||Preclinical - Patient cell culture||Actionable||In a preclinical study, DSP-5336 treatment inhibited blast colony formation in patient-derived acute myeloid leukemia cells harboring KMT2A-AFDN (reported as MLL-AF6) in culture (Blood (2021) 138 (Supplement 1): 3339).||detail...|